SONIVIE
SoniVie is developing an advanced denervation solution to treat pulmonary hypertension.
SONIVIE
Industry:
Health Care Health Diagnostics Medical
Founded:
2015-01-01
Address:
Rosh Ha'ayin, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.sonivie.com
Total Employee:
1+
Status:
Active
Total Funding:
2.5 M USD
Similar Organizations
Dxcover
The Future of Cancer Diagnostics
MediQuo
Spain’s 24-hour, 7-day-a-week medical chat application.
Quantitative Radiology Solutions
Quantitative Radiology Solutions offers advanced body-wide quantification of medical images.
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
Zebra Medical Vision
Zebra Medical Vision is a medical imaging and analytics platform.
Current Advisors List
Board_member
2000-01-01
Current Employees Featured
Charles S. Carignan CEO @ SoniVie
CEO
2019-03-01
Investors List
Accelmed
Accelmed investment in Venture Round - SoniVie
Official Site Inspections
http://www.sonivie.com Semrush global rank: 5.9 M Semrush visits lastest month: 1.4 K
- Host name: box5552.bluehost.com
- IP address: 162.241.218.94
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "SoniVie"
SoniVie - Crunchbase Company Profile & Funding
When was the last funding round for SoniVie? SoniVie closed its last funding round on Jan 9, 2023 from a Series C round. Who are SoniVie 's competitors? Alternatives and possible …See details»
Boston Scientific announces agreement to acquire SoniVie Ltd.
MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a …See details»
Team - SoniVie
SoniVie's lead product, TIVUS, is an investigational intravascular treatment that can be performed as part of a routine right heart catheterization for patients suffering from pulmonary arterial hypertension (PAH)See details»
Boston Scientific announces agreement to acquire SoniVie Ltd.
Mar 3, 2025 As a strategic investor in SoniVie, Boston Scientific currently holds an equity stake of approximately 10 percent. Therefore, the transaction consists of an upfront payment of …See details»
Sonivie, Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Sonivie, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Boston Scientific bets on ultrasound tech with SoniVie buyout
Mar 5, 2025 SoniVie was founded in 2014 at the initiative of the Accelmed Fund, led by Uri Geiger, as part of its strategy of building companies after identifying a need from large …See details»
SoniVie Ltd - LinkedIn
SoniVie announces advancements in its renal denervation program: REDUCED-1 pilot study results, radial access First-In-Human results, and FDA pivotal IDE approval of The THRIVE global studySee details»
SoniVie - Funding, Financials, Valuation & Investors - Crunchbase
SoniVie Ltd develops an advanced denervation solution. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has this organization …See details»
Boston Scientific Acquires SoniVie to Expand in Renal Denervation ...
Mar 6, 2025 Positioning for Leadership in Hypertension Treatment. Boston Scientific has announced a $540 million acquisition of SoniVie, maker of the Tivus ultrasound-based renal …See details»
Boston Scientific Agrees to Acquire Sonivie Ltd. For up to $540 …
2 days ago The agreement to acquire involves Boston Scientific paying about $360 million for the 90% of SoniVie’s equity that Boston Scientific does not already own, plus up to an …See details»
SoniVie 2025 Company Profile: Valuation, Investors, Acquisition
SoniVie General Information Description. Developer of a medical device designed to treat pulmonary hypertension with minimally invasive denervation procedures. The company's …See details»
Boston Scientific to Acquire SoniVie - Endovascular Today
Mar 3, 2025 As a strategic investor in SoniVie, Boston Scientific currently holds an equity stake of approximately 10%; therefore, the transaction will consist of an upfront payment of …See details»
Sonievie - VentureRadar
SoniVie is a medical device company developing the TIVUS™ Ultrasonic Denervation System as an innovative system for the treatment of pulmonary hypertension including pulmonary arterial …See details»
SoniVie Raises $60m in Round C Financing, and Appoints New …
Jan 9, 2023 SoniVie Ltd. (“SoniVie” or the “Company”), a medical device company developing a proprietary solution to treat hypertension, announced today the completion of a $60 million …See details»
SoniVie - Contacts, Employees, Board Members, Advisors & Alumni
SoniVie Ltd develops an advanced denervation solution. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
SoniVie Raises $60m in Round C Financing, and Appoints New …
Jan 9, 2023 SoniVie is a medical device company developing TIVUS™, the only ultra-sound denervation platform with active development programs in three therapeutic areas: pulmonary …See details»
SoniVie - Israeli Startup | Startup Nation Finder
Note that you need to have an email in this organization in order to claim the profile. Name* Work Email* (please provide your email in the organization) Position* Notes. Send Create Free …See details»
Boston Scientific Agrees to Acquire Sonivie Ltd. For up to $540 …
Mar 19, 2025 Boston Scientific recently announced it entered into a definitive agreement to acquire SoniVie Ltd. According to the press release, SoniVie is a privately held medical device …See details»
SoniVie Company Profile, Investors, & Funding | Lucidity Insights
Nov 2, 2015 SoniVie is a medical device company developing a system for the treatment of pulmonary hypertension (PAH). The companys therapeutic intravascular ultrasound (TIVUS) is …See details»
Boston Scientific snags renal denervation developer SoniVie for …
Mar 3, 2025 Last year, SoniVie put forward a pilot study of 40 participants in the U.S. and Israel, showing an average 12.0 mmHg reduction in ambulatory systolic blood pressure after three …See details»